NorthWest Biotherapeutics Inc (NWBO)

[ae kusterer]

Just asking IHUB analysts/ researchers/ NWBO investors what I am missing.

https://twitter.com/alphavestcap/status/1537424207960854530

ae kusterer

Wednesday, June 15, 2022 10:04:03 PM

Re: None

Post#
487271
of 487327
NWBO possible pending announcements:

Could Sawston be approved for 1000 per month production before DC VAX L commercial approval?


Here is my current thought process:

* Marnix says they have been working on MHRA approval since January(see 5/11/22 Telegram comment by an attendee at the NYAS NYC Mulholland presentation)
* In January they were just about to publish but they rightly decided to incorporate the external controls group
* they don’t need a publication to apply for approval they only submit actual raw data
* the process takes 150 days plus time between the stages
* Advent has been hiring steadily. First production people this winter now hiring international patient coordinators.
* ramping up manual production to 100
* working up to 1000 per month with Flaskworks
* They we’re running test runs with Flaskworks last summer.
So I’m thinking that they will have UK approval august-September if they started in January. Or end of year if they started in May (unlikely)








https://smithonstocks.com/could-there-have-been-hundreds-of-millions-or-even-more-than-a-billion-counterfeit-shares-of-northwest-biotherapeutics-created-through-illegal-naked-shorting/( How many NWBO shares are sold short?)





https://www.bbc.com/news/health-61709542

Patients in England can get early access to more cutting-edge medicines through a new fund.
The Innovative Medicines Fund (IMF) works like the existing Cancer Drugs Fund (CDF), fast-tracking promising treatments, even if they are expensive and have not yet been approved for routine NHS use.
It will cover potentially life-saving drugs for rare and genetic diseases.
The government has allocated up to £680m a year to be shared by the funds.
The IMF, like the CDF, will mean a newly approved medicine could be prescribed immediately, before final recommendations on it are drawn up by the advisory body that weighs the cost versus benefit of drugs used by the NHS - an organisation called NICE (the National Institute for Health and Care Excellence).
Patients would be able to access the treatment while data is collected for NICE to determine whether the medicine is affordable and effective enough to offer more widely.

@alphavestcap $nwbo https://t.co/9CRp1bisev

— alphavestcapital.com (@alphavestcap) June 13, 2022

(5/31/22 UCLA presentation suggests Dr.Liau's combo trial with DC Vax L and Keytruda shows greater efficacy than Dc Vax L alone.)

@litmpodcast ( agree? ) $nwbo @alphavestcap https://t.co/DYPeBXtSBp

— alphavestcapital.com (@alphavestcap) June 15, 2022

(Dr. Ashkan's trial data, Dr.Bosch's path to 1000 patient doses per month at Sawston)



https://investorshub.advfn.com/boards/read_msg.aspx?message_id=169159859 (The path to commercial approval in the UK which is potentially a $2.5-5.0 business.)

Reefrad

Thursday, June 16, 2022 9:07:20 AM

Re: None

Post#
487328
of 487340
From DI this morning:

XXXX,
As you can imagine we are working on all fronts to get to the end goal of approval. We did articulate ( can be found on virtual trials.com) the production side of DCVax-L at ASCO 2022,which is a key component to the entire therapy. As we achieve milestones or have well defined clarity,like the production side mentioned above, on the many fronts we are actively engaged in, we will certainly announce them. Sorry I cannot be of more help.
Best
Dave

Turner5

Thursday, June 16, 2022 9:17:57 AM

Re: None

Post#
487335
of 487343
Peer review article comes out this weekend. Production capabilities increase 10 fold. UK approves for sales and their health insurance pays in July. What's your guess for market cap end of July?

I'm guessing 5 billion/ 4 per share